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Progression of the smoking epidemic in
high-income regions and its effects on
male-female survival differences: a cohort-
by-age analysis of 17 countries
Maarten Wensink1,2*† , Jesús-Adrián Alvarez1†, Silvia Rizzi1,2, Fanny Janssen3,4 and Rune Lindahl-Jacobsen1,2
Abstract
Background: Of all lifestyle behaviours, smoking caused the most deaths in the last century. Because of the time
lag between the act of smoking and dying from smoking, and because males generally take up smoking before
females do, male and female smoking epidemiology often follows a typical double wave pattern dubbed the
‘smoking epidemic’. How are male and female deaths from this epidemic differentially progressing in high-income
regions on a cohort-by-age basis? How have they affected male-female survival differences?
Methods: We used data for the period 1950–2015 from the WHO Mortality Database and the Human Mortality
Database on three geographic regions that have progressed most into the smoking epidemic: high-income North
America, high-income Europe and high-income Oceania. We examined changes in smoking-attributable mortality
fractions as estimated by the Preston-Glei-Wilmoth method by age (ages 50–85) across birth cohorts 1870–1965.
We used these to trace sex differences with and without smoking-attributable mortality in period life expectancy
between ages 50 and 85.
Results: In all three high-income regions, smoking explained up to 50% of sex differences in period life expectancy
between ages 50 and 85 over the study period. These sex differences have declined since at least 1980, driven by
smoking-attributable mortality, which tended to decline in males and increase in females overall. Thus, there was a
convergence between sexes across recent cohorts. While smoking-attributable mortality was still increasing for
older female cohorts, it was declining for females in the more recent cohorts in the US and Europe, as well as for
males in all three regions.
Conclusions: The smoking epidemic contributed substantially to the male-female survival gap and to the recent
narrowing of that gap in high-income North America, high-income Europe and high-income Oceania. The
precipitous decline in smoking-attributable mortality in recent cohorts bodes somewhat hopeful. Yet, smoking-
attributable mortality remains high, and therefore cause for concern.
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Background
According to the Global Burden of Disease Study, in
2015 worldwide, one out of ten deaths was due to smok-
ing [1]. The same data suggest that smoking is the single
most important killer in the world with nearly twice as
many victims as the 5% deaths from AIDS, malaria and
tuberculosis combined [2]. As such, the smoking epi-
demic is having a huge impact on the world population
and on the individual risk of transitioning to the worst
possible health condition, i.e. to die [3].
The enormous increase and subsequent decline in
smoking prevalence and later smoking-attributable
mortality, and sex differences therein, has been
described in detail and termed the ‘smoking epidemic’
[4, 5]. The smoking epidemic model describes that
men in high-income countries (particularly the Anglo-
Saxon countries) were the first to take up smoking and
that smoking-attributable mortality rose some three
decades after the rise in smoking prevalence. Women
began to smoke later in time than males. Attention for
the negative health effects of smoking and associated
prevention campaigns led the proportion of males that
smoke to decline and the peak in the smoking preva-
lence among women to be considerably lower than for
men. Because of the various time lags, there is a stage
where the proportion of males dying from smoking be-
gins to decline, but the proportion of females continues
to rise (Fig. 1) [4, 5].
In the 1950s, over 50% of males in the United States
(US) were smokers. By 2015, this had changed to less
than 20%. For females, these numbers were 24% in the
1950s, versus 12–15% currently [6–11]. For Europe this
pattern was similar [7, 8]. Because the percentages of
smokers for males versus females are first divergent,
then convergent, in line with the theoretical model out-
lined above and in Fig. 1, and because high-income
countries have progressed furthest into the smoking
epidemic, we aimed to chart the progression of deaths
from smoking in high-income North-America, high-
income Europe and high-income Oceania, as well as
the way these deaths have influenced male-female sur-
vival differences.
The cohort perspective has been helpful in under-
standing the unfolding of the smoking epidemic [12].
Also, smoking has been shown to be a significant driver
of sex differences in survival [13–18]. Hence, we per-
formed a cohort-by-age analysis of smoking-attributable
mortality and investigated its effect on male-female life
expectancy differences. We hypothesized that the smok-
ing epidemic may have been the main contributor to the
widening and subsequent narrowing of the male-female
survival gap in high-income regions in the second half of
the twentieth century. We also hypothesized that the co-
hort perspective could reveal important aspects of the
smoking epidemic.
Methods
All-cause death rates and person-years at risk by age,
sex, year and country were retrieved from the Human
Mortality Database (HMD) [19], which collects these
data from national registries worldwide and, after quality
control, publishes these in a uniform format [20]. To es-
timate smoking-attributable mortality (see below), we
used lung cancer deaths, defined as malignant neoplasms
of trachea, bronchus and lung classified according to the
International Statistical Classification of Diseases,
Fig. 1 Schematic diagram of smoking epidemic, after reference 5. Males (in blue) take up smoking (solid line) at a steady pace until smoking-
attributable mortality surges (dashed line) and the proportion smoking starts to decline. Females (in red) take up smoking later than males and
reach a lower maximum proportion smoking. Smoking-attributable mortality in females is the last to increase to significant proportions. An
essential feature of the model is the large time gap between the act of smoking and dying from it
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Injuries and Causes of Death versions 7 through 10
(ICD-7: 162, 163; ICD-8 and ICD-9: 162; ICD-10: C33,
C34). Death counts from lung cancer were retrieved
from the World Health Organization (WHO) Mortality
Database [21]. Their cause-of-death statistics come from
national vital registration systems. The information is
compiled by the national authority and submitted to
WHO every year. WHO verifies that the data submitted
are coded with the official ICD codes [21].
Mortality data by age (50–85 years) and sex for the
populations of 17 high-income countries during the
period 1950–2015 were used. The focus on age 50 and
over stems from the technique that we used to indirectly
estimate smoking-attributable mortality (see below).
This method relies on deaths from lung cancer, which
are generally rare below age 50 [22]. Furthermore, previ-
ous research has shown that most of male-female mor-
tality differences are concentrated between ages 50 and
70 [13].
The method that we used to estimate smoking-
attributable mortality, the Preston-Glei-Wilmoth (PGW)
method [23] (see below), was based on 20 high-income
countries from around the world. We used much the
same data set, but we added recent data and excluded
three countries. We excluded Iceland because of its geo-
graphical location between Europe and North America.
We excluded countries that spent much of the 1950–
2015 period behind the Iron Curtain, because the coun-
tries missed out on the cardiovascular revolution for de-
cades, a phenomenon sometimes called the state
socialist syndrome [24]. This led us to exclude Hungary.
Japan was excluded because of its atypical smoking his-
tory [25]. For Portugal, cause-specific mortality data
were not available for the period 2004–2006. We im-
puted death rates for males and females for Portugal
during the period 2004–2006 (3 observations per sex in
total, details in Additional file 1) by taking into account
all the remaining information about death rates since
1950. We use a non-parametric method based on ran-
dom forest algorithms to perform the imputation (“mis-
sForest” R package, version 1.4 [26])”. The 17 remaining
countries were grouped into three geographical categor-
ies: high-income North America (US and Canada), high-
income Europe (Austria, Belgium, Denmark, Finland,
France, Italy, the Netherlands, Norway, Portugal, Spain,
Sweden, Switzerland and the UK), and high-income
Oceania (Australia and New Zealand).
The Preston-Glei-Wilmoth (PGW) method [23] was
used to appraise the proportion of deaths attributable to
smoking. This method assumes that “after adjusting for
sex and age, smoking is the only source of variation in
lung cancer death rates in the populations under consid-
eration” [23]. It estimates smoking attributable deaths
indirectly by assuming that lung cancer rates of smokers
and never-smokers match those observed among indi-
viduals in the Cancer Prevention Study II in the US. The
model then uses negative binomial regression to model
smoking attributable mortality from causes other than
lung cancer as a function of lung cancer mortality [23].
An analysis of deviance to assess the model fit is in-
cluded in the Additional file 1.
We then smoothed smoking-attributable mortality es-
timates with the penalized composite link model [27],
giving year-by-age estimates of the proportions of death
due to smoking for all 17 countries for males and fe-
males over age 50. We used such year-by-age estimates
to construct birth-cohorts’ mortality profiles between
1870 and 1965 for high-income North America, high-
income Europe and high-income Oceania [28]. Thus we
obtained the proportion of smoking-attributable mortal-
ity by sex, cohort and age (cohorts 1870–1965).
To shed light on how smoking-attributable mortality
affected period life expectancy, the way in which the sex
gap in survival is often analyzed [13], we calculated
period life expectancy between ages 50 and 85 (e50 ∣ 85,
the average number of years lived between ages 50 and
85) over the period 1950–2015 following standard






l 50ð Þ ;
where l(x) denotes number of survivors at age x. We
applied the life table calculations to all-cause mortality
rates (including smoking-attributable mortality) and to
non-smoking-attributable mortality rates (excluding
smoking-attributable mortality) for the three regions
and the different years. From those results we calcu-
lated male-female e50 ∣ 85 differences for all regions and
periods.
All analyses were run on R version 3.6.
Results
Between 1950 and 2015, the smoking epidemic caused a
total of 39 million deaths at ages 50–85 in the three
high-income geographical locations. Of these, 29 million
deaths were men and 10 million were women. The lar-
gest numbers of deaths attributable to smoking were in
high-income North America with 13 million men and 7
million women, followed by high-income Europe with
15 million and 3 million, respectively. In high-income
Oceania these numbers were 0.7 million and 0.2 million.
For males in high-income Europe, North America and
Oceania, we found a steep increase in the proportion of
smoking-attributable mortality from the cohorts born
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1870 up to about 1900–1910, when smoking-attributable
mortality was the highest (Fig. 2). For high-income
North America and Oceania, after reaching a peak for
the 1910–1930 cohorts, there was a large drop in the
proportion of smoking-attributable mortality in more re-
cent cohorts. For Europe, the upsurge was followed by a
stagnation period up to the most recent cohorts, where
a steep drop was seen.
For females in high-income North America, the up-
surge in smoking-attributable mortality was delayed by
about 30 years relative to males (Fig. 2). At the highest
ages, which are necessarily older cohorts, the peak in the
proportion of smoking-attributable mortality does not
seem to have been reached as yet, although some indica-
tion exists. For the younger ages, the peak was reached
for the 1930 cohorts, with a steep decline after, inter-
rupted only by the 1950 cohorts. For European females,
smoking-attributable mortality increased less steeply and
peaked later and lower than for North-American fe-
males. Any decline in smoking-attributable mortality in
European females is seen in the most recent cohorts
only, necessarily at younger ages. At higher ages, the
proportion of smoking-attributable mortality is still on
the increase. For Oceania, the pattern was similar to that
of the Europe, but without any significant drop to date.
In terms of absolute levels of smoking-attributable
mortality (rather than trends), smoking-attributable
mortality was higher in males than for females in Europe
for all age groups and all cohorts, even though for recent
cohorts the absolute differences were small (Fig. 2). For
the US and Oceania, smoking-attributable mortality was
higher for males than for females for most cohorts and
age groups, in particular those that drove recent
changes. However, for recent cohorts at relatively young
ages, smoking-attributable mortality was similar between
sexes, even slightly higher for females than for males.
We produced an alternative version of Fig. 2 with age
on the horizontal axis and each birth cohort represented
by a line (Additional file 1: Figure S3), providing a com-
plementary perspective of the smoking epidemic in the
high-income regions.
The effect of removing smoking-attributable mortality
on e50 ∣ 85 was similar for the three regions. For males, it
increased gradually for the years ~ 1950–1970, to up to
~ 2 years of partial life expectancy (Fig. 3, top panels).
This was particularly pronounced for Belgium, The
Netherlands and the UK, while the increase was smallest
for Sweden (Additional file 1: Figure S4). In the follow-
ing years the effect of removing smoking-attributable
mortality on e50 ∣ 85 remained more or less constant for
some decades until approximately 1990. Afterward it de-
clined to ~ 1 year for recent years. For females, the effect
of removing smoking-attributable mortality on e50 ∣ 85
was negligible for the years 1950–1970. Afterwards it
Fig. 2 Cohort-by-age analysis of the proportion of overall mortality that is attributed to smoking. Each birth cohort is on a single vertical line. For
males, ages are shaded from yellow (age 50) to turquoise (age 85). For females, ages are shaded from beige (age 50) to fuchsia (age 85). The
more recent a cohort, the smaller the number of age groups for which data are available (recent cohorts have not yet reached the higher ages).
Results given for high-income Europe (13 countries), high-income North America (2 countries) and high-income Oceania (2 countries)
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grew slowly but steadily to ~ 0.5 year. This was particu-
larly pronounced in the US, but less so in Europe and
Oceania.
Globally, over all three regions, the sex gap in e50 ∣ 85
was approximately 3 years in 1950, then increased to
some 4.5 years around 1975, and afterwards decreased
towards 2 years (Fig. 3, bottom panels). Omitting
smoking-attributable deaths, the male-female difference
in e50 ∣ 85 would have been approximately 2 years lower
at its peak and much more constant over time than with
smoking included (Fig. 3, bottom panels).
The contribution of smoking to male-female differ-
ences in life expectancy is now on the decline (Figs. 2
and 3). In some countries (Italy, New Zealand, Finland,
Spain), this is due to declining smoking attributable
mortality in males. In other countries (Sweden, Norway,
Iceland), this is mainly due to increasing smoking-
attributable mortality in females. Finally, there are coun-
tries (Canada, Austria, UK, US, Netherlands, Australia)
where the decline is caused by an approximately equal
contribution to each side of the e50 ∣ 85 gap (Additional
file 1: Figure S5).
Discussion
Our study advanced three main results. First, in all three
high-income regions, smoking explained up to 50% of
sex differences in period life expectancy between age 50
and 85 over the study period 1950–2015. Second, the
decline in these sex differences since approximately 1980
is largely driven by smoking-attributable mortality.
Third, whereas smoking-attributable mortality is still in-
creasing for many older female cohorts, it is declining
for females in the more recent cohorts in the US and
Europe, as well as for males in all three regions.
The massive impact of smoking on mortality is in line
with previous studies addressing smoking effects on
mortality at the population level; it has been found for
the United States [14], in European countries [12, 15,
30–35], and worldwide [36]. Smoking affects various
causes of death, such as various forms of cancer, cardio-
vascular disease and multifarious diseases of the respira-
tory tract [37, 38]. Smoking also explains important
differences in life expectancy between countries [39]. Fi-
nally, the historical trajectories of divergence between
life expectancy with and without smoking-attributable
Fig. 3 Upper panel: Historical development of period life expectancy between ages 50 and 85 (e50 ∣ 85, in years) for males (blue) and females (red)
with the observed mortality rates (solid), and when smoking-attributable mortality was omitted (dashed), for the three studied regions. Lower
panel: Sex differences in period e50 ∣ 85 with observed mortality (total population), and when smoking-attributable mortality was removed, for the
three studied regions
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mortality that we found are broadly similar to those pre-
viously found for specific countries [40].
Insights into the smoking epidemic across cohorts
Our cohort-by-age analysis of high-income regions con-
firmed the mortality element of the smoking epidemic
model [4, 5]: the increase in smoking-attributable mor-
tality started later among females than for males, and
resulted in a later peak at a lower level. Without con-
structing cohort profiles, we would not have been able
to trace two additional important regularities of the
smoking epidemic. First, while smoking-attributable
mortality in older cohorts still increased, a precipitous
decline in smoking-attributable mortality took place in
recent cohorts at younger ages. Second, smoking-
attributable mortality for males versus females con-
verged across cohorts.
The continuous increase in smoking-attributable mor-
tality in older female cohorts remains cause for concern.
It is an essential feature of the smoking epidemic,
though, that these deaths result from the high smoking
prevalence of women decades ago. More encouraging is
the decline in smoking-attributable mortality in recent
cohorts at younger ages. Also, smoking prevalence has
generally come down over the last decades in the studied
regions. For example, in Australia smoking prevalence in
females aged 15+ came down from 22.0% in 2000 to
12.4% in 2015 (for males, these numbers were 27 and
14.3%, respectively) [41].
In the same vein, current sex-specific smoking preva-
lence gives some indication of future sex-specific
smoking attributable mortality. In 2015 smoking preva-
lence generally remained higher in males than in fe-
males. For example, in 2015 32% of French men
smoked, versus 22% of females; in Germany, 25% of
males smoked versus 17% of females; while in the US
14% of males smoked versus 12% of females [7]. Conse-
quently, male smoking-attributable mortality is likely
to remain (or become again) higher than female
smoking-attributable mortality.
The smoking epidemic and the sex gap in life expectancy
In 1950 the sex gap in period e50 ∣ 85 was 2.0–3.5 years.
It subsequently grew to 4.3–4.5 years at the maximum
around 1970–1980, and then decreased to 1.8–2.5 years
in 2015 for the three regions. The rise, stagnation and
decline in the sex differences in survival has been de-
scribed in detail elsewhere [13, 16–18]. Smoking behav-
iour has been found to explain international differences
in the life expectancy sex gap [42–44]. We here show
that across high-income regions, almost no increase in
the sex gap would have occurred without smoking-
attributable mortality. Smoking-attributable mortality
caused almost all the increase and most of the decrease
in the sex gap over the study period.
Although the major part of the decline in the sex gap
hitherto is caused by the steep drop in smoking-
attributable mortality in males, more and more so this is
also due to the increases in smoking-attributable mortal-
ity in females overall. For all-causes mortality, in con-
trast, it has been found that a reduction in the male-
female life expectancy gap is, for most countries, due to
men dying at lower rates, rather than women at higher
rates [18, 45].
We suggest that we may not have seen the end of the
narrowing in e50 ∣ 85 sex differences in these regions yet.
To date, male smoking-attributable mortality generally
still exceeds that of females. Meanwhile, trends are
downward for males generally, while for females they are
upwards for older cohorts. This suggests scope for fur-
ther narrowing sex differences in e50 ∣ 85 in these regions.
However, the extent to which this may happen seems
limited because male smoking prevalence generally re-
mains higher nowadays than female smoking prevalence
(see above). Of course, smoking-attributable mortality is
not the only factor that affects the sex gap, and there is
evidence that mortality from some causes other than
smoking may currently be widening the gap [16]. Still,
smoking-attributable mortality could overwhelm the ef-
fect of mortality from other causes on the sex gap. This
could happen especially in countries with a high propor-
tion of women taking up smoking some decades ago,
where smoking-attributable mortality for men and
women could potentially cross over (e.g. U.K., Denmark
and the Netherlands) [8], as we have found for the most
recent cohorts in the US and Oceania.
Limitations
One clear limitation of our study is the indirect calcu-
lation of the smoking-attributable deaths. Such a limi-
tation is unavoidable: comparisons between different
methods to estimate smoking-attributable mortality
did not reveal a best-practice method [46, 47], and
even if good estimates of smoking prevalence are
available to potentially directly estimate smoking-
attributable mortality, other factors like smoking
intensity are often harder to measure and to take into
account in direct estimates.
Since the PGW method [23] extrapolates the lung
cancer rates of non-smokers from a US study to other
countries, there may be a bias in our estimates for
those other countries. Also, the PGW is based on study
participants that are more likely than the US overall
population to be Caucasian and middle class, and to
have achieved a relatively high level of education [47].
However, previous analyses have shown that the indir-
ect estimation by PGW resulted in roughly similar
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outcomes compared to other indirect estimation tech-
niques [30, 31, 48], so we are confident that our results
are broadly reliable. Results obtained making a modifi-
cation to the PGW method proposed by Rostron [49],
discussed in [50], are included in the Additional file 1.
Making this modification would not have affected our
main conclusion.
As a final limitation, our estimates of smoking-
attributable mortality were smoothed over ages, which
may lead to minor distortions. We do not expect that to
be the case here due to relatively regular source data.
Conclusion
While a sharp decrease in recent cohorts is a strong
positive development, smoking-attributable mortality for
both sexes has converged across cohorts to a level that
remains high. Males and females dying of smoking at
the same rate is not an end to the smoking epidemic. In
high-income regions, smoking remains a major killer.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12889-020-8148-4.
Additional file 1. Appendix.
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